Found 1 articles for: "European Country-Specific Reimbursement Requirements"

Subgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis

June 2022 | Volume 21 | Issue 6 | Original Article | 659 | Copyright © June 2022

Background: Biologic drugs are generally recommended for treating moderate-to-severe psoriasis. While eligibility criteria are primarily defined by clinical treatment guidelines, acce...
Read More